- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma. (Pubmed Central) - Nov 2, 2022
Lenvatinib re-administration after atezolizumab plus bevacizumab treatment can act as a double-edged sword, as it exerts an anti-tumor effect while being associated with potential liver function deterioration. However, this treatment sequence can be useful, and requires careful monitoring of the transitions in the liver function and the patient's performance status.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, IO biomarker: Micronodular Thymic Carcinoma with Lymphoid Stroma: A Case Report. (Pubmed Central) - Nov 1, 2022
Due to pleural metastasis, the patient was treated with lenvatinib 27 months postoperatively...This is the first report of a partially low-grade, GTF2I-negative MTC. Histological and genetic findings might be predictive of tumor prognosis.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Experience in the Treatment of Patients with Advanced Thymic Cancer () - Nov 1, 2022 - Abstract #IASLCACLC2022IASLC_ACLC_97;
Currently, in Japan, lenvatinib is regarded as one of the standard care for advanced or post-operative recurrent thymic cancer. However, its safety and efficacy for previously untreated advanced and post-operative cases with thymic cancer have not been proved yet.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus (clinicaltrials.gov) - Oct 31, 2022
P2, N=30, Not yet recruiting,
However, its safety and efficacy for previously untreated advanced and post-operative cases with thymic cancer have not been proved yet. Initiation date: Aug 2022 --> Nov 2022
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma. (Pubmed Central) - Oct 28, 2022
We also discuss clinical evidence for immunotherapy and pembrolizumab in ATC through the analysis of studies evaluating immunotherapy, lenvatinib and pembrolizumab lenvatinib association in ATC. In addition, we discuss the safety of this association and potential predictive biomarkers of efficiency.
- |||||||||| Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Review, Journal: Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma. (Pubmed Central) - Oct 28, 2022
Approximately half of patients with HCC, especially those at advanced disease stages, receive systemic therapies, including the tyrosine kinase inhibitors sorafenib and lenvatinib...In particular, the combination therapy with atezolizumab (an anti-PD-L1 antibody) and bevacizumab (an anti-VEGF antibody) significantly improved survival benefits compared with sorafenib as a single agent, a finding that has stimulated further preclinical and clinical development of immunotherapeutic approaches for treating HCC...Hence, combination therapies that could sensitize HCC to immunotherapy have become a growing area of investigation. In this review, we summarize recent advances in HCC immuno-oncology and review immunotherapeutic strategies that are under development for treating HCC.
- |||||||||| Journal: Advances in targeted and immune therapies for hepatocellular carcinoma (Pubmed Central) - Oct 28, 2022
Local therapy combined with targeted drugs (such as sorafenib and lenvatinib) or immune checkpoint inhibitors can significantly improve outcomes. Therefore, some progress has also been made in the study of single-agent or combination regimens as perioperative neoadjuvant therapy.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Resistance of Lenvatinib in Hepatocellular Carcinoma. (Pubmed Central) - Oct 28, 2022
Accordingly, it is necessary to determine factors associated with Lenvatinib resistance and explore solutions. In this review, we sought to explore the drug resistance mechanisms of Lenvatinib in liver cancer and methods to reduce drug resistance and summarized the recent achievements of Lenvatinib in liver cancer treatment.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Oct 28, 2022
P2, N=24, Recruiting,
In this review, we sought to explore the drug resistance mechanisms of Lenvatinib in liver cancer and methods to reduce drug resistance and summarized the recent achievements of Lenvatinib in liver cancer treatment. Not yet recruiting --> Recruiting
- |||||||||| Review, Journal: An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present). (Pubmed Central) - Oct 27, 2022
Six inhibitors have been approved for the treatment of RET-driven cancers: vandetanib, cabozantinib, lenvatinib, sorafenib, selpercatinib, and pralsetinib...It is imperative that the next iteration of RET inhibitors are developed to block common treatment resistant mutations. To accomplish this, RET inhibitors should be developed in concert with genomic profiling to ensure the most relevant clinical mutations are targeted.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial completion date, Trial primary completion date, IO biomarker: NeoPele: A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (clinicaltrials.gov) - Oct 27, 2022
P2, N=40, Recruiting,
To accomplish this, RET inhibitors should be developed in concert with genomic profiling to ensure the most relevant clinical mutations are targeted. Active, not recruiting --> Recruiting | Trial completion date: Mar 2025 --> Jan 2033 | Trial primary completion date: Jul 2023 --> Jan 2023
- |||||||||| carboplatin / Generic mfg., paclitaxel / Generic mfg.
Review, Journal: Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. (Pubmed Central) - Oct 26, 2022
The applicability of these retrospective studies to contemporary clinical practice is difficult in the setting of changing patient demographics, a better understanding of endometrial cancer drivers, and the recent approvals of immune checkpoint inhibitors and the combination of lenvatinib plus pembrolizumab in the second-line setting. The primary focus of this review is to distill the available data regarding platinum-doublet chemotherapy rechallenge and highlight recent pivotal developments in endometrial cancer treatment, as well as future directions.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
ASYMPTOMATIC CHEST WALL MASS RISING SUSPICION OF RECURRENCE IN PATIENT WITH HÜRTHLE CELL THYROID CANCER AFTER LOSS OF FOLLOW UP DURING COVID‐19 PANDEMIC () - Oct 26, 2022 - Abstract #ATA2022ATA_546;
We are presenting a case of asymptomatic chest wall mass concluded to be an osseous metastasis with underlying metastatic lymphadenopathy in the setting of history of Hürthle cell cancer and loss to follow up during decreased access to medical care. Adequate follow up for patients with thyroid cancer with high recurrence risk has become of outermost importance during ongoing COVID‐19 pandemic, and requires new mechanisms in place in order to minimize worsening metastatic disease as in case of the patient we presented.
- |||||||||| Mekinist (trametinib) / Novartis, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tafinlar (dabrafenib) / Novartis
UNUSUAL TYPE OF PAPILLARY THYROID CARCINOMA () - Oct 26, 2022 - Abstract #ATA2022ATA_533;
While the columnar cell variant of PTC is a rare aggressive variant characterized by a papillary structure but with a paucity of nuclear pseudo‐inclusion, PDTC is an intermediate between differentiated and anaplastic thyroid carcinoma. Even though Lenvatinib is the first line for advanced PTC/PDTC, targeted therapy is preferred due to lesser toxicities.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
NEOADJUVANT LENVATINIB THERAPY FOR INOPERABLE THYROID CANCER () - Oct 26, 2022 - Abstract #ATA2022ATA_435;
We demonstrate the potentials of neoadjuvant Lenvatinib therapy for inoperable TC. Caution has to be practiced in cases with locally advanced TC due to the rare reported cases of carotid blowout and aerodigestive fistulas in patients under Lenvatinib therapy.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATION CONFERS RESISTANCE TO LENVATINIB IN THYROID CANCER CELLS () - Oct 26, 2022 - Abstract #ATA2022ATA_340;
The results indicate that signal transduction via the EGFR pathway may be involved in the development of lenvatinib resistance in thyroid cancer cells. The inhibition of the EGFR pathway simultaneously by an EGFR inhibitor may have therapeutic potential for overcoming lenvatinib resistance in thyroid cancer.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
CHANGES IN PERIPHERAL BLOOD IMMUNE CELL POPULATION IN THYROID CANCER PATIENTS TREATED WITH LENVATINIB () - Oct 26, 2022 - Abstract #ATA2022ATA_133;
The current study reinforces the clinical effectiveness of lenvatinib in patients with RAI‐R DTC in real‐world clinical practice in the USA. There was a significant increase in the peripheral NK cell population after lenvatinib treatment in advanced thyroid cancer patients, which might be associated with a good response from lenvatinib treatment.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
LENVATINIB RESISTANT THYROID CANCER CELL LINES ARE CHARACTERIZED BY INCREASED MITOCHONDRIAL RESPIRATION () - Oct 26, 2022 - Abstract #ATA2022ATA_131;
TC cells characterized by a high‐OXPHOS metabolic profile are more prone to further activation of baseline and maximum mitochondrial respiration, as a mechanism of TKIs resistance, than cells relying on anaerobic glycolysis. Combination therapies with TKIs and OXPHOS inhibitors might be warranted to target TC resistance mechanisms.
- |||||||||| Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[ 177 LU]LU‐DOTAGA.(SA.FAPI) 2 THERAPY IN ADVANCED STAGE RADIOIODINE‐RESISTANT THYROID CANCERS OF FOLLICULAR AND PARAFOLLICULAR CELL ORIGINS () - Oct 26, 2022 - Abstract #ATA2022ATA_105;
Twenty ‐nine patients (mean age: 50 years, range: 32‐65y, males‐14, females‐15) with metastatic R‐R TC were prospectively recruited after disease progression was observed on standard treatments, including radioiodine therapy, tyrosine kinase inhibitors such as sorafenib, lenvatinib, vandetanib, and 177 Lu‐PRRT. [ 177 Lu]Lu‐DOTAGA.(SA.FAPi) 2 therapy is a promising salvage treatment option for the treatment of aggressive R‐R TC patients who have exhausted all standard line of treatments.
- |||||||||| Review, Journal, IO biomarker: Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective. (Pubmed Central) - Oct 25, 2022
The multi-kinase inhibitors (MKIs) lenvatinib and sorafenib are currently available as first-line treatment for advanced progressive RAI-R TC...Novel selective targeted therapies have been introduced for the treatment of RAI-R TC in selected cases: REarranged during Transfection (RET) inhibitors (selpercatinib and pralsetinib) and Tropomyosin Receptor Kinase (TRK) inhibitors (larotrectinib and entrectinib) have recently expanded the panorama of the therapeutic options. Moreover, immune checkpoint inhibitors (ICIs) have shown promising results, and they are still under investigation.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A Theranostic Metallodrug Modulates Immunovascular Crosstalk to Combat Immunosuppressive Liver Cancer. (Pubmed Central) - Oct 25, 2022
In this study, tyrosine kinase inhibitor lenvatinib (Len) was loaded into mesoporous FeO (mFe) nanoparticles (NPs), and bovine serum albumin (BSA) was attached to the NP surface to produce a metallodrug (BSA-mFe@Len NPs)...The metallodrug was able to modulate immunovascular TME for combating HCC via metalloimmunotherapy induced by the mFe NPs and Len's multiple functions (direct triggering of tumor apoptosis, vessel normalization, cytotoxic T-lymphocyte recruitment, and regulatory T-cell elimination). In vivo experiments showed that the metallodrug could significantly inhibit HCC growth and evoke long-term antitumor immune memory, paving a new avenue for treating advanced HCC patients.
|
